Physician profile
Bruce V Saylor
NPI 1316053846
$673.11
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $115 · 2021: $47.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $190.34 | 2019-2021 | |
| Mylan Specialty L.P. | $136.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.66 | 2019 | |
| Astellas Pharma US INC | $32.63 | 2019-2020 | |
| Sanofi Pasteur INC. | $29.57 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $20.44 | 2019 | |
| Daiichi Sankyo INC. | $18.14 | 2021 | |
| Merck Sharp & Dohme LLC | $16.62 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $15.25 | 2019 | |
| Lilly USA, LLC | $15.25 | 2021 | |
| Currax Pharmaceuticals LLC | $14.99 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.51 | 2019 | |
| Shire North American Group INC | $13.88 | 2019 | |
| Dexcom, INC. | $13.14 | 2020 | |
| Genentech USA, INC. | $12.67 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Saylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.